Piramal Pharma Limited’s (BSE: 500302; PPL) contract development and manufacturing organization (CDMO), Piramal Pharma Solutions (PPS), has entered into an agreement to acquire a 100% stake in fellow India-based Hemmo Pharmaceuticals.
The accord provides for an upfront consideration of 7.75 billion rupees ($105.6 million) and earn-outs linked to achievement of milestones.
As PPS continues to expand and grow its capabilities and position as a leading CDMO, this acquisition marks PPS’ foray into the development and manufacturing of peptide active pharmaceutical ingredients (APIs), a capability that complements PPS’ existing service offering.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze